全文获取类型
收费全文 | 1286109篇 |
免费 | 93894篇 |
国内免费 | 2005篇 |
专业分类
耳鼻咽喉 | 18359篇 |
儿科学 | 42513篇 |
妇产科学 | 37992篇 |
基础医学 | 188437篇 |
口腔科学 | 35551篇 |
临床医学 | 109271篇 |
内科学 | 253193篇 |
皮肤病学 | 26588篇 |
神经病学 | 100011篇 |
特种医学 | 50296篇 |
外国民族医学 | 367篇 |
外科学 | 198773篇 |
综合类 | 27051篇 |
现状与发展 | 1篇 |
一般理论 | 308篇 |
预防医学 | 93850篇 |
眼科学 | 29202篇 |
药学 | 98470篇 |
1篇 | |
中国医学 | 2514篇 |
肿瘤学 | 69260篇 |
出版年
2018年 | 12012篇 |
2015年 | 11759篇 |
2014年 | 16199篇 |
2013年 | 24643篇 |
2012年 | 34041篇 |
2011年 | 36435篇 |
2010年 | 21464篇 |
2009年 | 20234篇 |
2008年 | 35401篇 |
2007年 | 38339篇 |
2006年 | 38906篇 |
2005年 | 38188篇 |
2004年 | 36770篇 |
2003年 | 35754篇 |
2002年 | 35264篇 |
2001年 | 58366篇 |
2000年 | 59931篇 |
1999年 | 50968篇 |
1998年 | 14399篇 |
1997年 | 12912篇 |
1996年 | 13196篇 |
1995年 | 12457篇 |
1994年 | 11867篇 |
1993年 | 10949篇 |
1992年 | 41203篇 |
1991年 | 40588篇 |
1990年 | 40076篇 |
1989年 | 38914篇 |
1988年 | 36285篇 |
1987年 | 35549篇 |
1986年 | 33908篇 |
1985年 | 32308篇 |
1984年 | 24088篇 |
1983年 | 20961篇 |
1982年 | 12491篇 |
1981年 | 11005篇 |
1980年 | 10269篇 |
1979年 | 22758篇 |
1978年 | 15967篇 |
1977年 | 13818篇 |
1976年 | 13038篇 |
1975年 | 14259篇 |
1974年 | 16763篇 |
1973年 | 16149篇 |
1972年 | 15383篇 |
1971年 | 14284篇 |
1970年 | 13254篇 |
1969年 | 12778篇 |
1968年 | 12020篇 |
1967年 | 10527篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
151.
L Laforest E Van Ganse G Devouassoux S Chretin L Osman G Bauguil Y Pacheco G Chamba 《The European respiratory journal》2006,27(1):42-50
French asthma patients may be supervised by general practitioners (GPs) and/or specialists. Therefore, this study examined asthma management in patients exclusively supervised by specialists (SPE), GPs, (GP) and both (GP+SPE group), and compared the findings. Asthma patients were consecutively recruited in 348 pharmacies. Each patient completed a questionnaire providing data on personal characteristics, asthma management, perception of disease and asthma supervision. Asthma control was measured using the Asthma Control Test. Questionnaires were linked to computerised records of medications which had been dispensed before inclusion in the study. From the 1,256 patients (mean age = 36.1 yrs, 54.3% females), 11.4, 36.6, and 52.0% were placed in the SPE, GP, and GP+SPE groups, respectively. During the previous 4 weeks, most patients in the SPE group were properly controlled (52.2 versus 26.4 and 21.5% in GP and GP+SPE groups, respectively). The SPE group made more use of fixed combinations of long-acting beta agonist and inhaled corticosteroid, while receiving less short-acting beta agonists, antitussives and antibiotics. Striking differences in symptoms and asthma management were observed according to the type of asthma supervision. The current results strongly support the need to improve the management of asthma in primary care, and the coordination of care between general practitioners and specialists. 相似文献
152.
153.
Tom G. Bolwig 《Acta psychiatrica Scandinavica》2006,114(6):445-445
154.
155.
BMP-2 gene polymorphisms and osteoporosis: the Rotterdam Study. 总被引:7,自引:0,他引:7
Marco Medici Joyce Bj van Meurs Fernando Rivadeneira HongYan Zhao Pascal P Arp Albert Hofman Huibert Ap Pols André G Uitterlinden 《Journal of bone and mineral research》2006,21(6):845-854
After reported associations of variations in the BMP-2 gene with osteoporosis in small populations, we studied the association of the BMP-2 gene polymorphisms Ser37Ala and Arg190Ser with osteoporosis in 6353 men and women from the Rotterdam Study. We did not observe an association of these variants with BMD, bone loss, hip structural analysis parameters, and fracture risk. INTRODUCTION: Bone morphogenetic protein 2 (BMP-2) plays a role in osteoblast differentiation. BMP-2 gene variation has previously been associated with osteoporosis in various small populations, but current evidence remains inconclusive about the exact association with osteoporosis. Therefore, we studied the association of two polymorphisms located in the BMP-2 gene (Ser37Ala and Arg190Ser) and haplotypes defined by these polymorphisms with BMD, rates of bone loss, parameters of hip structural analysis (HSA), and fractures in the Rotterdam Study, a large prospective cohort study of diseases in the elderly. MATERIALS AND METHODS: Databases were searched for polymorphisms and haplotype blocks in the BMP-2 gene region. Allele frequencies for Ser37Ala and Arg190Ser were determined in 60 blacks and 110 Chinese from Coriell panels. Genotype data on Ser37Ala and Arg190Ser were available for 6353 individuals from the Rotterdam Study population. Haplotype alleles defined by Ser37Ala and Arg190Ser were inferred using PHASE software. Genotype and haplotype analyses for BMD (measured at the lumbar spine and femoral neck), bone loss per year (measured at the femoral neck), and HSA were performed using AN(C)OVA. Fractures were analyzed using a Cox proportional-hazards model and logistic regression. All outcomes were adjusted for age, height, and weight. RESULTS: Allele frequencies were 2.5% for Ala37 and 40.2% for Ser190, whereas haplotype allele frequencies were 57.28% (Ser37Arg190), 40.19% (Ser37Ser190), 2.50% (Ala37Arg190), and 0.02% (Ala37Ser190). For BMD, bone loss, HSA outcomes, and (incident) fractures, no differences could be seen between genotype and haplotype groups. Conclusions: In this large population-based cohort of Dutch whites, we conclude that the BMP-2 Ser37Ala and Arg190Ser polymorphisms or haplotypes thereof are not associated with parameters of osteoporosis. 相似文献
156.
Mark S. Wallace Steven G. Charapata Robert Fisher Michael Byas‐Smith Peter S. Staats Martha Mayo Dawn McGuire David Ellis 《Neuromodulation》2006,9(2):75-86
Objective. The safety and efficacy of intrathecal (IT) ziconotide was studied in a randomized, double‐blind, placebo‐controlled trial. Materials and Methods. Patients (169 ziconotide, 86 placebo) with severe chronic nonmalignant pain unresponsive to conventional therapy and a visual analog scale of pain intensity (VASPI score) ≥ 50 mm were treated over a 6‐day period in an inpatient hospital setting. Initial starting dose was 0.4 µg/hour and was titrated to analgesia or intolerance (maximum dose 7.0 µg/hour). The starting and maximum doses were reduced to 0.1 µg/hour and 2.4 µg/hour, respectively, due to adverse events (AEs). Results. The mean percent reduction in VASPI score from baseline was 31.2% and 6.0% for ziconotide‐ and placebo‐treated patients, respectively (p ≤ 0.001). During the initial titration phase, a significantly greater percentage of patients in the ziconotide group compared to the placebo group reported AEs, including abnormal gait, amblyopia, dizziness, nausea, nystagmus, pain, urinary retention, and vomiting. Conclusion. Ziconotide provided significant analgesia in patients for whom conventional therapy failed. However, there was a considerable incidence of ziconotide‐associated AEs due to the rapid titration and high doses administered. 相似文献
157.
158.
159.
160.